CClinicalTrials.gg
Status unknownNCT03465124FLAMEUpdated Mar 7, 2019

Evaluation of Central Macular Thickness in Femtosecond Laser-assisted Cataract Surgery

An interventional study of Femtosecond Laser and Manual Cataract Surgery in Age Related Cataracts and Cystoid Macular Edema, sponsored by Medical University of Vienna. Status unknown at 1 site in Austria. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-03-07.

Sponsored by Medical University of Vienna · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The investigational device is an approved femtosecond laser (FSL) device with an integrated imaging system to perform certain steps of the cataract procedure. The FSL will perform anterior capsulotomy and lens fragmentation in individuals suffering from age-related cataract with need of cataract surgery.

Cataract surgery will be performed in subjects who have signed an informed consent form. Macula thickness will be measured with Spectralis OCT on screening date.

Postoperative examinations will be implemented in accordance with the approved investigational plan on subjects and includes: visual acuity, slitlamp examination, retinal oct imaging and quantitative autofluorescence.

02

Conditions studied

  • Age Related Cataracts
  • Cystoid Macular Edema
03

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Bilateral Age-related cataract necessitating lens extraction and posterior IOL implantation
  • Age 40 and older (females of childbearing age will be interviewed if pregnancy is possible)

Exclusion criteria

Exclusion Criteria:

  • Corneal abnormality
  • Preceding ocular surgery or trauma
  • Uncontrolled glaucoma
  • Proliferative diabetic retinopathy
  • Macular degeneration
  • Iris neovascularization
  • History of uveitis/iritis
  • Microphthalmus
  • Recurrent intraocular inflammation of unknown etiology
  • Blind fellow eye
  • Uncontrolled systemic or ocular disease
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Femtosecond Laser assisted Cataract Surgery

    Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order.

    Device: Femtosecond Laser

  • Active comparator
    Manual Cataract Surgery

    Manual Cataract Surgery will be performed in contralateral (to LCS) eye of patient with bilateral age-related cataract.

    Other: Manual Cataract Surgery

Interventions

  • DeviceFemtosecond Laser

    Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order. Contralateral eye will receive conventional cataract surgery

  • OtherManual Cataract Surgery

    conventional cataract surgery as control

05

What researchers measure

Primary outcomes

  1. Central Macular Thickness

    Difference in Central Macular Thickness (CMT) between Femtosecond Laser-assisted Cataract Surgery (LCS) to Manual Cataract Surgery (MCS)

    Time frame: Baseline to 6 weeks postoperative

Secondary outcomes

  1. Influence of lens density on quantitative autofluorescence

    Influence of lens density on quantitative autofluorescence will be assessed in qAF units. Images will be recorded after volume scans for each eye on designated visits. Quantitative Autofluorescence quantifies natural fundus autofluorescence with a Spectralis HRA+OCT. This method uses the same wavelength and confocal scanning laser ophthalmoscope as fundus autofluorescence (488nm; maximum power: 280 µW) and can be used to determine the integrity and vitality of the retinal pigment epithelium which is important for nourishment the retina.

    Time frame: Baseline to 1 weel, 3 weeks and 6 weeks postoperative

  2. Central Macular Thickness

    Difference in Central Macular Thickness (CMT) between Femtosecond Laser-assisted Cataract Surgery (LCS) to Manual Cataract Surgery (MCS)

    Time frame: Baseline to 1 week, 3 weeks, 6 weeks postoperative

06

Study locations

1 site
  • Medical University of Vienna
    Vienna, 1090, Austria
07

References and documents

Publications

  • Reiter GS, Schwarzenbacher L, Schartmuller D, Roggla V, Leydolt C, Menapace R, Schmidt-Erfurth U, Sacu S. Influence of lens opacities and cataract severity on quantitative fundus autofluorescence as a secondary outcome of a randomized clinical trial. Sci Rep. 2021 Jun 16;11(1):12685. doi: 10.1038/s41598-021-92309-6. PubMed 34135449 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03465124
Lead sponsor
Medical University of Vienna
Responsible party
Rupert Menapace (Principal Investigator, Medical University of Vienna) — Principal investigator
First posted
Mar 14, 2018
Start date
Mar 26, 2018
Primary completion
Feb 19, 2019
Completion
Apr 6, 2019 (estimated)
Last update
Mar 7, 2019

Study contacts

Rupert Menapace, MD
principal investigator · Medical Universitiy of Vienna

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion